BioVie to Present Long COVID Trial Results on November 5
The pharmaceutical company will share Phase 2 clinical findings for its drug bezisterim at an upcoming workshop in Bethesda.
Updated on Oct. 26, 2026 in COVID-19
Live Poll
Should the government prioritize funding for rapid clinical testing of new drugs for health crises?
BioVie will present Phase 2 trial results for its investigational drug bezisterim during the RECOVER-TLC Hybrid Workshop on November 5, 2026. The study focused on treating adults suffering from Long COVID symptoms.
Why it matters
The findings aim to support the RECOVER-TLC Initiative, which seeks to expedite the development of effective medical treatments for those living with Long COVID. Researchers hope the data will guide the design of a necessary Phase 3 confirmatory study.
The ADDRESS-LC study utilized 22 clinical outcome measures to assess 200 participants receiving 20 milligrams of oral bezisterim twice daily. Approximately 78% of the trial cohort exhibited at least one primary symptom domain such as severe fatigue or cognitive impairment.
The players
BioVie
This pharmaceutical company is focused on developing therapies for chronic diseases and liver conditions.
National Institute of Allergy and Infectious Diseases
This federal research institute conducts and supports medical research to better understand, treat, and prevent infectious and immunologic diseases.
Foundation for the National Institutes of Health
This non-profit organization connects the public and private sectors to support the mission of the National Institutes of Health.
US Department of War
This federal agency provided the grant funding that supported the clinical investigation conducted during the ADDRESS-LC trial.
Dr. Penelope Markham
This lead investigator is scheduled to present the latest research findings regarding the ADDRESS-LC clinical trial at the upcoming workshop.
The details
The ADDRESS-LC trial, supported by a $13.13 million grant from the US Department of War, indicated a trend toward improvement in patients with severe fatigue, post-exertional malaise, or cognitive impairment. The investigational drug is designed to cross the blood-brain barrier to target inflammation, showing similar safety profiles to the placebo group.
Timeline
November 5, 2026: Dr. Penelope Markham presents the trial findings at the RECOVER-TLC Hybrid Workshop.
The Big Picture
The clinical findings represent a contribution to the ongoing research under the RECOVER-TLC Initiative. This study marks a step in the scientific effort to find targeted interventions for complex post-viral conditions.
Patients currently experiencing Long COVID symptoms may find that these findings inform future treatment options as the drug moves toward potential Phase 3 testing. However, the treatment is not yet clinically approved, and individuals should continue consulting their healthcare providers for established care plans.
The takeaway
The ADDRESS-LC trial highlights the potential for anti-inflammatory treatments to mitigate the debilitating cognitive and physical symptoms associated with Long COVID. Patients and their families should follow upcoming Phase 3 trial developments to understand the future availability of new therapeutic options.
Further reading
Find more clinical updates in the COVID-19 section.
Source note: This article includes information reported by Proactiveinvestors NA.
Live Poll
Should the government prioritize funding for rapid clinical testing of new drugs for health crises?
